What is it about?
The selection of the aluminum-based adjuvant may impact on the production of epitope-specific antibodies. In our case, gp120-specific antibodies were generated with Aluminum hydroxide adjuvant but not with aluminum phosphate. This is something relevant for the development of multiantigenic vaccine candidates to elicit pathogen-specific antibodies and also for the development of monoclonal antibodies.
Featured Image
Why is it important?
This paper shows that in multiantigenic vaccine formulations it is difficult to predict epitope exposure when using a particular aluminum-based adjuvant. Moreover, testing of different aluminum-based adjuvants might show even on/off antibody responses. Our findings and previous studies suggest that selection of the best aluminum-containing adjuvant for mixtures of antigens must be based on experimental evidences.
Perspectives
This paper highlight the fact that when selecting the best aluminum-based adjuvant for a particular multiantigenic vaccine formulation it is also important to consider epitope exposure and not only stability of the formulation because a differential adsorption of the antigens might impact on the antibody production.
Enrique Iglesias
Centro de Ingenieria Genetica y Biotecnologia
Read the Original
This page is a summary of: The Selection of the Aluminum-based Adjuvant Reconfigures the Exposure of the Target Antigen in the Multiantigenic Formulation TERAVAC, Drug Delivery Letters, January 2017, Bentham Science Publishers,
DOI: 10.2174/2210303106666161004145427.
You can read the full text:
Contributors
The following have contributed to this page
